Pulse 探索 nav.journalClub 辩论趋势研究者期刊

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

首页探索 nav.journalClub 趋势

⌘+K

Novel Substituted Tetrahydropyrrolooxazolones as RIPK1 Inhibitors | Synapse

April 24, 2026ACS Medicinal Chemistry Letters0 citations

View Full Paper

Novel Substituted Tetrahydropyrrolooxazolones as RIPK1 Inhibitors

JRJian RongMinistry of Education of the People's Republic of China SLSteven H. LiangGeorgia Institute of Technology

Key Points

The aim is to evaluate the efficacy of tetrahydropyrrolooxazolones as inhibitors of RIPK1 for therapeutic use.
Synthesis of novel tetrahydropyrrolooxazolones
Formation of pharmaceutical compositions
Assessment of therapeutic applications for RIPK1-related diseases
Tetrahydropyrrolooxazolones show promise as effective RIPK1 inhibitors.
Developed compositions demonstrate potential therapeutic benefits for related diseases.

Abstract

This patent discloses tetrahydropyrrolooxazolones as novel receptor-interacting protein kinase 1 (RIPK1) inhibitors as potential treatments for RIPK1-related diseases. It provides details in the synthesis of the tetrahydropyrrolooxazolones, pharmaceutical compositions, and therapeutic applications for RIPK1-related diseases.

问 AI

Like

Bookmark

Share

View Full Paper

问 AI

Like

Bookmark

Share

View Full Paper

Cite This Study

Rong et al. (Tue,) studied this question.

synapsesocial.com/papers/69eb084f553a5433e34b36f2 https://doi.org/https://doi.org/10.1021/acsmedchemlett.6c00188